Vanguard reports 0 shares in MacroGenics filing
MacroGenics Inc: The Vanguard Group filed Amendment No. 6 to its Schedule 13G/A, stating it beneficially owns 0 shares of MacroGenics common stock, equal to 0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MacroGenics Inc: The Vanguard Group filed Amendment No. 6 to its Schedule 13G/A, stating it beneficially owns 0 shares of MacroGenics common stock, equal to 0% of the class.
The filing explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report holdings separately; Vanguard states those entities pursue the same investment strategies previously followed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did The Vanguard Group report for MacroGenics (MGNX)?
Who signed the amendment on behalf of Vanguard?
AI-generated analysis. How Rhea-AI works. Not financial advice.